Derivative Group: 2021 / 2022 Annual report
Hin Sang Group Logs $1.7 Million Net Loss in FY22
03:20 AM EDT, 06/29/2022 (MT Newswires) -- Hin Sang Group's (HKG:6893) loss for the year ended March 31 amounted to HK$13.1 million ($1.7 million), compared with the HK$36.8 million net loss logged in
Derivative group: annual results announcement for the year ended March 31, 2022
Hin Sang Expects Decrease in FY22 Net Loss; Shares Climb 3%
11:59 PM EDT, 06/23/2022 (MT Newswires) -- Hin Sang Group (International) Holding (HKG:6893) is expecting to log a consolidated net loss of HK$14 million ($1.8 million) for the year ended March 31, co
Derivative groups: inside information-expected loss reduction
Derivative group: announcement of board meeting
Derivative Group  is now trading at HK $0.305, down 10.29%.
Phoenix New Media Hong Kong stocks | as of 11:49, the derivative Group  was at HK $0.305, down 0.035 Hong Kong dollars or 10.29% from yesterday's closing price, with a turnover of 600 Hong Kong dollars, with a high price of 0.305 Hong Kong dollars today and a lowest price of 0.305 Hong Kong dollars. according to yesterday's closing price, the 10-day average price is 35 Hong Kong dollars, the 50-day average price is 0.35 Hong Kong dollars, the current price-earnings ratio is 0.00 times earnings, and the 14-day strength index is 50.00.
Hin Sang Group Unit Ties Up with Hongli Homologous Biotechnology to Open Chain Stores in China
07:15 AM EST, 12/30/2021 (MT Newswires) -- Hin Sang Group (International) (HKG:6893) subsidiary Hin Sang Health and Medical (Guangdong) partnered with Hongli Homologous Biotechnology (Weihai) to set
Derivative Group (06893.HK) partnered with Hong Li to open a mainland chain of "Pengzu Derivatives Museum".
Derivative Group (06893.HK) announced that affiliated derivative Guangdong has entered into a cooperation agreement with Hongli homologous Biotechnology to set up a new company, Pengzu Derivatives Museum (Guangdong) Brand Management Company, which will open a chain store called "Pengzu Derivatives Museum" in the mainland to exclusively sell products supplied by derivative Guangdong. Among them, derivative Guangdong will contribute 1 million yuan in kind in the form of the right to use the registered trademark of "Pengzu derivative Museum", while Hongli will contribute 9 million yuan in cash and will own 10% and 90% of the brand management company, respectively.
Derivative Group (06893.HK) plans to join hands with Hongli homologous Biotechnology (Weihai) to establish Pengzu derivative Museum (Guangdong) Brand Management Company.
Derivative Group (06893.HK) announced that on December 29th, 2021, derivative Health Medicine (Guangdong) Co., Ltd. ("derivative Guangdong", a wholly-owned subsidiary of the company) and Hongli Tongyuan Biotechnology (Weihai) Co., Ltd. entered into a cooperation agreement to establish a new company, Pengzu Derivatives Museum (Guangdong) Brand Management Co., Ltd. Under the cooperation agreement, the brand management company will open a chain store called Peng Zuyan Hall in the people's Republic of China to exclusively sell products supplied by derivative Guangdong. The board of directors believes that through the establishment of a brand management company and the opening of a wide range of chain stores in China